. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Cytotherapy. 2014 Sep;16(9):1280–1293. doi: 10.1016/j.jcyt.2014.05.025

Table I. Comparison of two novel in-utero hematopoietic stem cell transplantation regimens using human donor cells in the sheep model.

Group 1. CD34⁺ engraftment using plerixa for and prior MSC transplantation				Group 2. CD34⁺ engraftment using plerixa for and prior MSC and CD34⁺ transplantation
Sheep no.	Surgery 1 Day 59	Surgery 2 Day 66	Human Cells in PB (%)	Sheep no.	Surgery 1 Day 59	Surgery 2 Day 66	Human Cells in PB (%)	Avg.
2757	1,800,000 MSC	250,000 CD34⁺	2.80	2738	1,000,000 MSC 50,000 CD34⁺	80,000 CD34⁺	19.54	20.96
2758	1,800,000 MSC	250,000 CD34⁺	3.03	2739	1,000,000 MSC 50,000 CD34⁺	80,000 CD34⁺	22.37	20.96
2759	1,800,000 MSC	800,000 CD34⁺	2.32	2740^*	1,000,000 MSC 67,000 CD34⁺	167,000 CD34⁺	8.77^*	8.27^*
2761	1,800,000 MSC	750,000 CD34⁺	1.45	2741^*	1,000,000 MSC 67,000 CD34⁺	167,000 CD34⁺	7.62^*
2762	1,800,000 MSC	750,000 CD34⁺	4.65	2742^*	1,000,000 MSC 67,000 CD34⁺	167,000 CD34⁺	8.41^*
Median			2.80	Median			8.77
Standard deviation			1.17	Standard deviation			7.12

Fetal sheep were transplanted with cord blood-derived CD34⁺ cells with plerixa for treatment one week after transplanting bone marrow-derived MSCs with or without accompanying CD34⁺ cells from the same cord blood unit. Peripheral blood was collected for analysis at 11 weeks post-transplantation (during gestation) except animals 2740, 2741, and 2742 at 5 weeks post transplantation.

Multi-lineage human hematopoietic engraftment in the peripheral blood was assayed as described in methods.